학술논문

Lucifensin, klíčová molekula larvální terapie
Document Type
TEXT
Source
Vesmír | 2011 Volume:90 (141) | Number:5
Subject
Language
Czech
Abstract
Lucifensin - the key player of larval therapy. The beneficial use of fly larvae in healing chronic infected wounds has been known since ancient times, but reintroduction of standard, rutine maggot therapy in clinical practice at hundreds of hospitals around the world dates back only to the 1990s. The application of Lucilia sericata larvae into infected wound results in removal of necrotic tissue, elimination of infecting microorganisms, disinfection of the wound, and stimulation of wound granulation and repair. Many researchers have focused on the study of antimicrobial compounds secreted/excreted by maggots to the wound. The antimicrobial peptide of larval immune system named lucinfensin secreted/excreted to the wound was for the first time identified by scientists of the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic. Discovery of lucinfensin contributes to the understanding of healing principles of larval therapy.